“…Keski-Säntti et al [62] reported that PET/CT conducted about 3 months after therapy has sensitivity, specificity, positive predictive value (PPV), and NPV of 59%, 94%, 71%, and 91% for detecting residual disease in the primary sites, and 95%, 100%, 100%, and 93% in the nodes, respectively. Recently, Anderson et al [63] used SUV measurements at 60, 90, and 120 minutes and found that change of maximum SUV slope after 90 minutes more accurately identified non-recurrence in positive or equivocal sites than using SUV at one point. This finding suggests that quantitative measures from pharmacokinetic analysis of PET data may provide more reliable and accurate imaging markers to identify residual tumor after therapy.…”